Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sumitovant Biopharma completes acquisition of Myovant Sciences
The deal was announced on 23 October 2022. Sumitovant has acquired all outstanding shares of Myovant it did not own through the all-cash deal. Following the completion of
The deal was announced on 23 October 2022. Sumitovant has acquired all outstanding shares of Myovant it did not own through the all-cash deal. Following the completion of
The financing round, which brings the total funds raised by the firm to $143.5m, was led by EQT Life Sciences, investing from Droia Ventures, Sanofi Ventures and the
F-star is being acquired for a total cash consideration of approximately $161m or $7.12 per share. Currently, F-star is undertaking Phase II trials in Europe and the US.
Under the agreement terms, Volastra receives an exclusive global license (ex-China) for the development and commercialisation of sovilnesib. Amgen will, in exchange, receive an upfront mix of cash
Selagine is a spin-out company from the University of Illinois at Chicago (UIC), while Grifols is a provider of plasma-derived medicines. A biologic drug, an immunoglobulin eye drop
RAG-17 has been designed to act on and knockdown SOD1 expression in patients with pathogenic mutations that are known to cause ALS. The chemistry of the therapeutic is
Designed to modify SBMA through several mechanisms, AJ201 is currently in a Phase Ib/IIa study in the US to treat spinal and bulbar muscular atrophy (SBMA), which is
The company claimed that its 10mL presentation is the only FDA-approved ready-to-administer 10mL pre-filled syringe available. Nexus Pharmaceuticals CEO and president Usman Ahmed said: “We are pleased to
Under the collaboration, both the companies will work together for further AI and machine learning-driven efforts in therapeutic development. The partnership aims to gather insights more precisely that
Upadacitinib (RINVOQ, 45mg [induction dose] and 15mg and 30mg [maintenance doses]) is intended for those patients who have not shown adequate response, lost response or were intolerant to